<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02183610</url>
  </required_header>
  <id_info>
    <org_study_id>1218.7</org_study_id>
    <nct_id>NCT02183610</nct_id>
  </id_info>
  <brief_title>Investigation of the Metabolism and Pharmacokinetics of 10 mg [14C] BI 1356 Administered Orally Compared to 5 mg [14C] BI 1356 Administered Intravenously in Healthy Male Volunteers</brief_title>
  <official_title>Investigation of the Metabolism and Pharmacokinetics of 10 mg [14C] BI 1356 Administered Orally Compared to 5 mg [14C] BI 1356 Administered Intravenously in Healthy Male Volunteers in an Open Label, Single-dose and Parallel Study Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To determine the basic pharmacokinetics of BI 1356 BS, its metabolite CD 1750 XX and
      radioactivity including excretion mass balance, excretion pathways and metabolism following
      the intravenous and oral administration of [14C] BI 1356 BS
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of individual time course profiles of [14C] radioactivity in whole blood, plasma, urine and faeces</measure>
    <time_frame>before and up to 264 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of individual time course profiles of BI 1356 BS and its metabolite CD 1750 XX in plasma and urine</measure>
    <time_frame>before and up to 264 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and extent of excretion mass balance based on the total radioactivity in urine and faeces</measure>
    <time_frame>prior to and up to 120 h after start of administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CBlood cell/Cplasma ratio of [14C] -radioactivity</measure>
    <time_frame>1:30, 3, 24 and 72 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the plasma protein binding of total [14C] radioactivity in human plasma samples ex vivo</measure>
    <time_frame>1:30 and 3 hours post drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum concentration of the analyte(s) in plasma)</measure>
    <time_frame>before and up to 264 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>tmax (time from dosing to the maximum concentration of the analyte(s) in plasma)</measure>
    <time_frame>before and up to 264 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte(s) in plasma over the time interval from 0 to the time of the last quantifiable data point)</measure>
    <time_frame>before and up to 264 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-infinity (area under the concentration-time curve of the analyte(s) in plasma over the time interval from 0 to infinity)</measure>
    <time_frame>before and up to 264 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>λz (terminal rate constant in plasma)</measure>
    <time_frame>before and up to 264 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 (terminal half-life of the analyte(s) in plasma)</measure>
    <time_frame>before and up to 264 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MRTpo and MRT, respectively (mean residence time of the analyte(s) in the body after p.o. and i.v. administration)</measure>
    <time_frame>before and up to 264 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F (apparent/total clearance of the analyte(s) in plasma following extravascular and intravenous administration)</measure>
    <time_frame>before and up to 264 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular or intravenous administration (F=1) respectively)</measure>
    <time_frame>before and up to 264 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>feurine,0-tz (amount of analyte excreted in urine within the time interval zero to tz (=120 h) in % of dose)</measure>
    <time_frame>prior to and up to 120 h after start of administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>fefaeces,0-tz (amount of analyte excreted in faeces within the time interval zero to tz (=120 h) in % of dose)</measure>
    <time_frame>up to 120 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CLR,0-tz (renal clearance of analyte)</measure>
    <time_frame>prior to and up to 120 h after start of administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fa (drug absorption based on radioactivity data)</measure>
    <time_frame>up to 264 h after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 47 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of tolerability by investigator on a 4-point scale</measure>
    <time_frame>on day 12 during ambulant visit or on day of discharge on day 13, 14 or 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of local tolerability of the infusion by investigator on a 6-point scale</measure>
    <time_frame>after start of infusion up to day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>[14C] BI 1356 as oral (p.o.) solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>[14C] BI 1356 solution for i.v. infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C] BI 1356 as oral (p.o.) solution</intervention_name>
    <arm_group_label>[14C] BI 1356 as oral (p.o.) solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C] BI 1356 solution for i.v. infusion</intervention_name>
    <arm_group_label>[14C] BI 1356 solution for i.v. infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Healthy males according to the following criteria: Based upon a complete medical history,
        including the physical examination, vital signs Blood Pressure (BP), Pulse Rate (PR)),
        12-lead Electrocardiogram (ECG), clinical laboratory tests

          -  Age &gt;=30 and Age &lt;=60 years

          -  BMI &gt;=18.5 and BMI &lt;=29.9 kg/m2 (Body Mass Index)

          -  Signed and dated written informed consent prior to admission to the study in
             accordance with Good clinical practice (GCP) and the local legislation

        Exclusion Criteria:

          -  Any finding of the medical examination (including BP, PR and ECG) deviating from
             normal and of clinical relevance

          -  Any evidence of a clinically relevant concomitant disease

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          -  History of relevant orthostatic hypotension, fainting spells or blackouts

          -  Chronic or relevant acute infections

          -  History of relevant allergy/hypersensitivity (including allergy to drug or its
             excipients)

          -  Intake of drugs with a long half-life (&gt; 24 hours) within at least one month or less
             than 10 half-lives of the respective drug prior to administration or during the trial

          -  Use of drugs which might reasonably influence the results of the trial based on the
             knowledge at the time of protocol preparation within 10 days prior to administration
             or during the trial

          -  Participation in another trial with an investigational drug within two months prior to
             administration or during the trial

          -  Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt; 3 pipes/day)

          -  Inability to refrain from smoking during the stay in the trial centre

          -  Alcohol abuse (more than 60 g/day)

          -  Drug abuse

          -  Blood donation (more than 100 mL within four weeks prior to administration or during
             the trial)

          -  Excessive physical activities (within one week prior to administration or during the
             trial)

          -  Any laboratory value outside the reference range that is of clinical relevance

          -  Inability to comply with dietary regimen of study centre

          -  A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a
             QTc interval &gt;450 ms);

          -  Male subjects must agree to minimize the risk of female partners becoming pregnant
             from the dosing day until 3 months after the completion of the study. Acceptable
             methods of contraception for male volunteers include a vasectomy no less than 3 months
             prior to dosing, barrier contraception or a medically accepted contraceptive method.
             For female partners of male volunteers, acceptable methods of contraception include
             intra-uterine device, tubal ligation, hormonal contraceptive since at least two months
             and diaphragm with spermicide

        Exclusion criteria specific for this study:

          -  Veins unsuitable for infusion and blood sampling

          -  PR interval &gt;220 ms or QRS interval &gt;120 ms

          -  Female gender
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2014</study_first_submitted>
  <study_first_submitted_qc>July 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 7, 2014</last_update_submitted>
  <last_update_submitted_qc>July 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

